title: [Monoclonal antibodies in the treatment of malignant lymphoma].
abstract: Monoclonal antibodies (MoAbs) have different mechanism and adverse effects compared with cytotoxic agents. The introduction of MoAbs has improved the treatment potency to malignant lymphoma without decreasing the quality of life. However, there are many questions to be answered: What is the profound mechanism of MoAbs? How about their long-term adverse effects? What is the best medication pattern in different disease types?
authors.affiliation: Department of Medical Oncology, Cancer Hospital, CAMS and PUMC, Beijing 100021, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Niu
authors.forename: Yuan-Kai
authors.initials: YK
authors.lastname: Shi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods; D015195:Drug Design; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D016499:Radioimmunotherapy; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000069283:Rituximab; C422802:ibritumomab tiuxetan